Developing a system for the continuous manufacture of red blood cells

开发连续生产红细胞的系统

• 批准号: 105649
• 金额: $ 10.19万
• 依托单位: CELLULAREVOLUTION
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105649
• 关键词: Developing; system; continuous; manufacture; red

Red blood cells (RBCs) are currently harvested from donors and represent the most common form of cell-based therapy. There is an urgent need for RBCs for transfusion, and this demand is predicted to rise as the population continues to have longer life expectations. In light of this, there has been considerable research advancement to generate RBCs in vitro starting from different precursor cells, however there are no technologies enabling the scaling-up of the process in order to meet the current and future demand of cells. In addition, high-scale production of RBCs is relevant for other applications/markets. For instance, it has been shown that organs that are re-perfused with blood substitutes have a greater transplant success and clean meat companies would be interested in adding a safe, animal-free and affordable source of RBCs to improve the taste and texture of their products. In light of this, CellulaREvolution is willing to undertake industrial research to test/adapt its smart coating technology for the continuous production of RBCs.CellulaREvolution is a company that recently spun-out from Newcastle University with a highly innovative technology that allows the continuous manufacture of cells. Our novel approach is to move from the traditional batch culture (with its overly complicated ways to increase surface area) to a continuous culture system where cells are produced unremittingly. Cells are currently grown in batches, the size of each batch limited by the surface area upon which the cells are attached (e.g. flask size). Importantly, batch culture technologies are not able to meet the demand for cells for different applications that we believe our continuous technology can address.This project aiming at exploring our process for the continuous manufacture of RBCs, can have a great impact on the end users (i.e. patients) while helping the company growing, raising more investments, generating know-how and IP. Moreover, after its completion, other companies could also benefit from this project since we aim to test the newly developed technology via collaborations/partnerships.

红细胞（RBC）目前从供体中收获，代表了最常见的基于细胞的治疗形式。迫切需要红细胞输血，随着人口继续延长寿命，预计这种需求将增加。有鉴于此，从不同的前体细胞开始在体外产生RBC的研究已经取得了相当大的进展，但是没有技术能够扩大该过程以满足当前和未来的细胞需求。此外，红细胞的大规模生产与其他应用/市场相关。例如，已经证明，用血液替代品重新灌注的器官具有更大的移植成功率，清洁肉类公司将有兴趣添加安全，无动物和负担得起的红细胞来源，以改善其产品的味道和质地。有鉴于此，CellulaREvolution愿意进行工业研究，以测试/调整其智能涂层技术，用于连续生产红细胞。CellulaREvolution是一家最近从纽卡斯尔大学分拆出来的公司，拥有高度创新的技术，可以连续生产细胞。我们的新方法是从传统的分批培养（以其过于复杂的方式增加表面积）转移到连续培养系统，在该系统中细胞不断产生。细胞目前分批生长，每批的大小受细胞附着的表面积（例如烧瓶大小）限制。重要的是，批量培养技术无法满足我们相信我们的连续技术可以解决的不同应用对细胞的需求。该项目旨在探索我们的红细胞连续生产工艺，可以对最终用户（即患者）产生巨大影响，同时帮助公司发展，筹集更多投资，产生专有技术和知识产权。此外，在项目完成后，其他公司也可以从该项目中受益，因为我们的目标是通过合作/伙伴关系测试新开发的技术。